Business
Halozyme Reports Second Quarter 2021 Results
- Raising 2021 Revenue Guidance to $425-$445 Million from $375-$395 Million, GAAP Earnings Per Share Guidance to $1.55-$1.70 from $1.25-$1.40 and Non-GAAP
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"- Raising 2021 Revenue Guidance to $425-$445 Million from $375-$395 Million, GAAP Earnings Per Share Guidance to $1.55-$1.70 from $1.25-$1.40 and Non-GAAP Earnings per Share Guidance to $1.85-$2.00 from $1.55-$1.70 -\n - Second Quarter Revenue of $136.5 Million with GAAP Diluted Earnings per Share of $0.62 and Non-GAAP Diluted Earnings per Share of $0.66 -\n - Record Quarterly Royalties in the Second Quarter of $45.8 Million Representing 189% Growth over Second Quarter 2020 -\n\n\nSAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook.\n\"Our excellent start to 2021 continued in the second quarter with strong quarterly growth resulting in record quarterly revenues from royalties and the signing of our eleventh collaboration and license agreement,\" said Dr. Helen Torley, president and chief executive officer. \"Our recently announced collaboration with ViiV Healthcare demonstrates the potential for our ENHANZE® technology to meet evolving patients' needs by creating long-acting drugs that facilitate rapid, large volume subcutaneous injections of small molecule drugs. This collaboration also highlights the potential for ENHANZE® in new disease areas like infectious disease. As a result of this new collaboration and our strong results to date, we are pleased to share that we are raising our guidance for revenues and earnings for the year.\"\n Recent Partner Highlights: \nIn July 2021, Janssen received U.S. Food and Drug Administration (FDA) approval for DARZALEX FASPRO® (daratumumab and hyaluronidase - fijh) in combination with pomalidomide and dexamethasone for patients with multiple myeloma after first or subsequent relapse, marking the sixth indication for DARZALEX FASPRO® in the treatment of multiple myeloma. In June 2021, Halozyme announced a global collaboration and license agreement with ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc. This license gives ViiV exclusive access to Halozyme's ENHANZE® technology for four specific small and large molecule targets for the treatment and prevention of HIV. Under the terms of the agreement, Halozyme received an upfront payment of $40 million and ViiV is obligated to make...